| Title |
Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C
|
|---|---|
| Published in |
Drugs, March 2018
|
| DOI | 10.1007/s40265-018-0895-5 |
| Pubmed ID | |
| Authors |
Young-A Heo, Emma D. Deeks |
| Abstract |
A fixed-dose combination of the hepatitis C virus (HCV) NS5B polymerase inhibitor sofosbuvir, the HCV NS5A inhibitor velpatasvir and the HCV NS3/4A protease inhibitor voxilaprevir (sofosbuvir/velpatasvir/voxilaprevir; Vosevi®) is approved in the EU for the treatment of chronic HCV genotype 1, 2, 3, 4, 5 or 6 infection in adults. In the phase III POLARIS trials, in patients who had HCV genotype 1-6 infection with or without compensated cirrhosis, overall rates of sustained virological response at 12 weeks post-treatment (SVR12) with sofosbuvir/velpatasvir/voxilaprevir were high after 8 weeks of treatment in direct-acting antiviral (DAA)-naïve patients and 12 weeks of treatment in DAA-experienced patients. However, 8 weeks of sofosbuvir/velpatasvir/voxilaprevir was inferior to 12 weeks of sofosbuvir/velpatasvir in cirrhotic or non-cirrhotic DAA-naïve patients with HCV genotype 1, 2, 4, 5 or 6 infection and non-cirrhotic DAA-naïve patients with HCV genotype 3 infection, mostly due to an insufficient treatment period. Sofosbuvir/velpatasvir/voxilaprevir was generally well tolerated, with most adverse events being of mild or moderate intensity. The most common adverse events included headache, fatigue, nausea and diarrhoea. In conclusion, sofosbuvir/velpatasvir/voxilaprevir is an important and effective option for the treatment of HCV genotype 1-6 infection in adults, especially those who have previously failed a DAA therapy with or without an HCV NS5A inhibitor. |
Mendeley readers
The data shown below were compiled from readership statistics for 53 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 53 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 19% |
| Student > Bachelor | 6 | 11% |
| Student > Master | 6 | 11% |
| Researcher | 5 | 9% |
| Other | 3 | 6% |
| Other | 4 | 8% |
| Unknown | 19 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 12 | 23% |
| Biochemistry, Genetics and Molecular Biology | 7 | 13% |
| Chemistry | 5 | 9% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Nursing and Health Professions | 2 | 4% |
| Other | 5 | 9% |
| Unknown | 19 | 36% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 September 2022.
All research outputs
#7,657,585
of 23,312,088 outputs
Outputs from Drugs
#1,355
of 3,298 outputs
Outputs of similar age
#134,128
of 334,515 outputs
Outputs of similar age from Drugs
#22
of 32 outputs
Altmetric has tracked 23,312,088 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,298 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,515 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.
We're also able to compare this research output to 32 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.